All 1 tracked stories fall under one category: funding. ASX is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Vitrafy Life Sciences appears in 1 tracked Cross-Sector story from June 12, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Vitrafy Life Sciences
All 1 tracked stories fall under one category: funding. ASX is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Vitrafy Life Sciences appears in 1 tracked Cross-Sector story from June 12, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Vitrafy Life Sciences. Shared-story counts are live from our verified record — not editorial picks.
Vitrafy Life Sciences raised $30 million in a discounted institutional placement, aiming to disrupt the US blood storage market with its Guardion integrated platform. The raise, at a 31.6% discount, funds fleet expansion and US sales ahead of a 2027 legacy technology phase-out.